18-year follow-up of extended newborn screening for metabolic and endocrine disorders | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals


Journal of Computational Methods in Molecular Design


18-year follow-up of extended newborn screening for metabolic and endocrine disorders

Author(s): Sook Za Kim

To follow up Korean patients with inborn blunders of metabolism and endocrine problems and assess the long-term effectiveness of extended new child screening in South Korea. Method: From January 2000 to December 2017, tandem mass spectrometry and fluorometry were employed in extended new born screening (NBS). The NBS software bought dried blood spots from 283,626 babies 48 hours after delivery and screened for galactosemia, congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH) and 50 preventable inborn errors of amino acid, fatty acid and organic acid metabolism. Result: 28 cases of amino acid disorders, 75 cases of natural acid disorders, 27 instances of fatty acid disorders, and 51 cases of urea cycle disorders had been ascertained via NBS and subsequent confirmatory laboratory tests.

Conclusion and Discussion: Patients with amino acid metabolic disorders, galactosemia, CH or CAH had been more likely to have higher long-term outcome, if detected early through NBS and actively managed. Early management of maple syrup urine disease led to much better prognosis in over 90% whilst in 32% of organic academia’s (MMA, PPA, IVA, GA) cases, early intervention nonetheless resulted in developmental lengthen and neurological problems. Fatty acid problems confirmed assorted outcomes; those with EMA and MCAD had excellent prognosis, however those with VLCAD had serious neurological troubles and notably greater mortality. Despite the NBS program, 75% with urea cycle disorders experienced serious neurological complications, and compared to different metabolic disorders, extra sufferers died. The nation-wide NBS software need to be accompanied through comprehensive long term management and follow-up as nicely as medical doctor training of inborn errors of metabolism for higher outcome. The introduction of established screening of all new child toddlers for treatable congenital diseases was closely linked to the story of phenylketonuria, a sickness for which Horst Bickel, in 1953, first described a fantastic dietetic treatment. It was soon realized that the long-term success of this therapy surely depends on its initiation before the onset of clinically overt disease. In the early 1960s, Robert Guthrie and Ada Susi developed a bacteriological check for phenylalanine that became recognized around the world as the Guthrie test. From about 1968 onward, all new-born toddlers in (West) Germany were examined in this way for an expanded serum awareness of phenylalanine. Galactosemia was once the second congenital metabolic ailment to be included in the screening program. The software underwent further main expansions to encompass thyrotropin screening for congenital hypothyroidism in the 1970s and, in some of the German federal states, 17-OH-progesterone screening for adrenogenital syndrome in the 1990s. As greater and extra instances of congenital metabolic defects came to be effectively treated, it was located that the established neonatal screening program did not cover the existing need. An ever-increasing variety of diseases were understood to be treatable in principle if the remedy may want to be initiated in the pre-symptomatic stage, i.e., earlier than the earliest overt manifestations of the disease, and this may want to only occur if there were a screening technique for early detection. Yet these ailments were of distinctly varied types, and most uncommon as well; thus, with conventional diagnostic technology, many man or woman assessments would have been required, and the case-finding cost (i.e., the whole value of all the tests required in the populace to diagnose the ailment in a single patient) would have been prohibitively high. The vital development that circumvented this trouble was the introduction of tandem mass spectrometry (TMS) for neonatal screening in the 1990s. TMS made it possible to test for a massive wide variety of problems of amino acid metabolism, organic acid metabolism, and fatty acid degradation concurrently in a single procedure carried out on a single blood specimen